ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

ANALYSIS OF FREQUENCY OF RE-BLEEDING AFTER SUCCESSFUL ENDOSCOPIC MANAGEMENT OF ESOPHAGEAL VARICES IN CIRRHOTIC PATIENTS

AUTHORS:

Dr Abdul Hannan Javaid, Dr Waqas Anjum, Dr Samra Gull

ABSTRACT:

Introduction: Portal hypertension (PH), defined as hepatic venous pressure gradient of more than 5 mmHg, is one of the major complications of the liver cirrhosis. Clinical complications of portal hypertension, including gastro esophageal varices, become evident once hepatic venous pressure gradient exceeds 10 mmHg. Objectives of the study: The basic aim of the study is to analyze the frequency of re-bleeding after successful endoscopic management of esophageal varices in cirrhotic patients. Methodology of the study: This retrospective observational study was conducted in Nishtar hospital, Multan during 2018 with the permission of ethical committee of hospital. The data were collected from 80 endoscopic band ligation. Both males and females were included who have evidence of cirrhosis on the basis of clinical history, examination, biochemical and radiological investigations, had first episode of upper gastrointestinal bleeding secondary to esophageal varices and had undergone band ligation. Results: 80 cases with history of cirrhosis and previous band ligation were chosen for the study. Out of which 49 (61.3%) were male and 31 (38.8) were of female gender. Causes of liver cirrhosis were identified as 63(78.8%), 5(6.3%) and 12(15%) for hepatitis C, hepatitis B and Non B, Non C respectively. Out of 80, 13(16.2%) patients presented with rebleeding in 4 weeks post band ligation. Conclusion: In this study, EVBL was found to be an effective modality in reducing the frequency of rebleeding in cirrhotic patients. Severity of liver disease and number of variceal columns were independent risk contributing to re-bleeding.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.